Stocks · News reference

TD Cowen Initiates Coverage On Faeth Therapeutics with Buy Rating

Sep 9, 2026, 2:30 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

SEC EDGARSep 17, 2026, 8:15 PMSEC EDGAR
8-K filing — Faeth Therapeutics, Inc. (FTH)
Filed: 2026-09-17 AccNo: 0001193125-26-394360 Size: 150 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
FTH
BenzingaSep 16, 2026, 12:10 PMBenzinga Newsdesk
Guggenheim Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $70
Guggenheim analyst Brad Canino initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $70.
FTH
BenzingaSep 14, 2026, 5:26 PMBenzinga Newsdesk
LUCID CAPITAL MARKETS Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $59
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $59.
FTH